Search

Your search keyword '"COAGULANTS"' showing total 96 results

Search Constraints

Start Over You searched for: Descriptor "COAGULANTS" Remove constraint Descriptor: "COAGULANTS" Journal thrombosis and haemostasis Remove constraint Journal: thrombosis and haemostasis
96 results on '"COAGULANTS"'

Search Results

1. Molecular Characterization of Two Homozygous Factor VII Variants Associated with Intracranial Bleeding

2. High-Dose Epinephrine Enhances Platelet Aggregation at the Expense of Procoagulant Activity

3. Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A

4. A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects

5. Transglutaminase Activities of Blood Coagulant Factor XIII Are Dependent on the Activation Pathways and on the Substrates.

6. Cholesterol Starvation and Hypoxia Activate the FVII Gene via the SREBP1-GILZ Pathway in Ovarian Cancer Cells to Produce Procoagulant Microvesicles

7. Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists

8. Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study

9. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

10. Procoagulant State in Current and Former Anabolic Androgenic Steroid Abusers

11. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

12. Suppressive Role of Tissue Factor Pathway Inhibitor-alpha in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength

13. Tissue Factor Coagulant Activity is Regulated by the Plasma Membrane Microenvironment

14. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A

15. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B

16. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system

17. Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems

18. Editors’ Choice 2016 papers in Thrombosis and Haemostasis

19. Procoagulant Effects of Low-Level Platelet Activation and Its Inhibition by Colchicine

20. Effects of Low- and High-Dose Chemotherapy Agents on Thrombogenic Properties of Extracellular Vesicles Derived from Breast Cancer Cell Lines

21. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A

22. Half-life extension technologies for haemostatic agents

23. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings

24. CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitro

25. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate

26. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

27. Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation

28. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients

29. Molecular circuits in thrombosis and inflammation

30. Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome

31. Investigating clearance mechanisms for recombinant activated factor VII in a perfused liver model

32. Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma

33. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A

34. Contribution of platelet microparticles generation assay to the diagnosis of type II heparin-induced thrombocytopenia

35. Prophylaxis in people with haemophilia

36. Prolonged in-vivo half-life of factor VIIa by fusion to albumin

37. An observational study of sucrose-formulated recombinant factor VIII for Japanese patients with haemophilia A

38. Clearance of von Willebrand factor

39. Haemophilus somnus activation of brain endothelial cells: Potential role for local cytokine production and thrombosis in central nervous system (CNS) infection

40. Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure

41. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

42. Exchange transfusion activates coagulation and alters the coagulation profile in newborn infants

43. Evidence for the benefits of prophylaxis in the management of hemophilia A

44. Towards optimization of selective photothermolysis: prothrombotic pharmaceutical agents as potential adjuvants in laser treatment of port wine stains - A theoretical study

45. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood

46. Prothrombinase enhancement through quantitative and qualitative changes affecting very low density lipoprotein in complex with C-reactive protein

47. Lepirudin prevents lethal effects of Shiga toxin in a canine model

48. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab

49. Beneficial Effect of the Active Form of Vitamin D3 against LPS-induced DIC but not against Tissue-factor-induced DIC in Rat Models

50. The Impact of Glu102Lys on the Factor X Function in a Patient with a Doubly Homozygous Factor X Deficiency (Gla14Lys and Glu102Lys)

Catalog

Books, media, physical & digital resources